Evidence map›Paper›PMID 34669094›Full record

ArticleInternational ophthalmology2022

Juvenile idiopathic arthritis-associated uveitis in the era of biological therapy: how the disease changed in more than 20 years of observation in a tertiary referral center in Rome (Italy).

E Del Giudice, C Simio, A Scala, A Di Coste, G La Torre, L Spadea, R Lubrano, M Duse, M P Paroli

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Disease Damage in Juvenile Idiopathic Arthritis.Indian journal of pediatrics · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

E Del GiudiceDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Polo Pontino, Italy.
C SimioDepartment of Sense Organs, Eye Clinic, Uveitis Unit, Sapienza University of Rome, V.le del Policlinico 155, 00161, Rome, Italy.
A ScalaDepartment of Sense Organs, Eye Clinic, Uveitis Unit, Sapienza University of Rome, V.le del Policlinico 155, 00161, Rome, Italy.
A Di CosteDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
G La TorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
L SpadeaDepartment of Sense Organs, Eye Clinic, Uveitis Unit, Sapienza University of Rome, V.le del Policlinico 155, 00161, Rome, Italy.
R LubranoDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Polo Pontino, Italy.
M DuseDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
M P ParoliDepartment of Sense Organs, Eye Clinic, Uveitis Unit, Sapienza University of Rome, V.le del Policlinico 155, 00161, Rome, Italy. mariapia.paroli@uniroma1.it.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the ophthalmological characteristics in a Juvenile idiopathic arthritis (JIA) cohort and to evaluate how therapeutic advances have changed the course of the uveitis.

methodsAnalysis of a retrospective cohort study of consecutive JIA pediatric patients including JIA-associated uveitis (JIA-U) and comparison with a previous study in the same uveitis center assessed before the wide-spread of biological therapy.

resultsThe total of 49 JIA patients were analyzed, of whom 18 JIA-U, compared with a JIA-U past cohort of 66 patients. Systemic corticosteroids were used significantly less in the current JIA-U group (p = 0.008) than in the past one. JIA-U present cohort was on therapy more frequently with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) than the past group (p = 0.039), mostly treated with methotrexate (93.3%). Furthermore, a larger use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) was described in the current JIA-U group (p = 0.005) also associated with csDMARDs (p = 0.003). Adalimumab was used more (72.7%) in the present JIA-U cohort compared to a larger treatment with infliximab (61.5%) in the past (p = 0.005). Higher number of uveitis recurrences was observed in the previous cohort compared to the current one (p = 0.005). Fewer complications were described in this study than in the previous: posterior synechiae (p = 0.007), cataract (p < 0.001), band keratopathy (p < 0.001), and elevated intraocular pressure (IOP) (p = 0.047).

conclusionCurrent therapies reduced the uveitis recurrences and ocular complications including cataract due also to the lower use of corticosteroids. The new close collaboration with the pediatric rheumatologic center in the same University has contributed to the care improvement and decrease of uveitis complications.

Indexed as

Arthritis, JuvenileUveitisBiological TherapyChildHumansItalyRetrospective StudiesRisk FactorsRomeTertiary Care CentersBiological therapyJuvenile idiopathic arthritisOcular complicationsUveitisVisual prognosis

Identifiers

PMID34669094
PMCPMC8917035
OpenAlexW3207485860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.